Neovii and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon, in China and Japan.
Grafalon is indicated in solid organ transplant for prevention and treatment of acute rejection, graft-vs-host disease (GvHD) in stem cell transplant (SCT) and in the treatment of aplastic anemia.
Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon in these key markets to advance the clinical development for the prevention of chronic GvHD in SCT.
Grafalon is currently approved for prevention of rejection and the treatment of acute steroid resistant rejection in solid organ transplant in China.
Grafalon, has been used for over 30 years to treat patients, and is currently available in over 50 countries worldwide. Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.
"We are very enthusiastic to work with Mundipharma as a partner to develop Grafalon in China further by developing its indication for use in stem cell transplantation and further solidifying the position of Grafalon as a leading treatment for solid organ transplant patients in China," Juergen Pohle, Neovii CEO said.